Press Releases :: Journey Medical Corporation (DERM)

NOW APPROVED: EMROSI™ (Minocycline Hydrochloride) Extended-Release Capsules, 40mg

Learn More

Jan 20, 2023

Journey Medical Corporation Appoints Joseph Benesch as Interim Chief Financial Officer

Jan 10, 2023

Journey Medical Corporation Completes Enrollment in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Dec 20, 2022

Journey Medical Corporation Announces Positive Comparative Pharmacokinetic (PK) Data for DFD-29

Dec 5, 2022

Journey Medical Corporation to Participate in Cantor Medical & Aesthetic Dermatology, Ophthalmology & MedTech/Diagnostic Conference

Nov 10, 2022

Journey Medical Corporation Reports Third Quarter 2022 Financial Results and Recent Corporate Highlights

Nov 3, 2022

Journey Medical Corporation to Announce Third Quarter 2022 Financial Results on November 10, 2022

Oct 4, 2022

Journey Medical Corporation to Participate in Upcoming October 2022 Investor Conferences

Aug 30, 2022

Journey Medical Corporation Announces 50% Enrollment Milestone Achieved in Phase 3 Clinical Trials Evaluating DFD-29 (Minocycline Modified Release Capsules 40 mg) for the Treatment of Papulopustular Rosacea

Aug 9, 2022

Journey Medical Corporation Reports Second Quarter 2022 Financial Results and Recent Corporate Highlights

Aug 3, 2022

Journey Medical Corporation to Announce Second Quarter 2022 Financial Results on August 9, 2022

rss_feed News RSS